Global Kratom Coalition Applauds Florida's Ban on Dangerous Concentrated Synthetic 7-OH Products
Natural leaf kratom was not included or under scrutiny in today's announcement.
'Florida's leadership in taking swift action against dangerous synthetic 7-OH opioid products is a landmark moment in protecting public health,' said Matthew Lowe, Executive Director of the Global Kratom Coalition. 'We strongly support enforcement against synthetic 7-OH opioid products, which pose real risks of abuse, dependence, and overdose. Importantly, similar to the FDA's recommendation, this action draws a clear line between natural kratom leaf products and novel lab-produced potent derivatives like 7, by clearly ensuring that natural kratom leaf is not affected by the emergency scheduling.'
This announcement comes after FDA Commissioner Dr. Marty Makary stated on July 29 that the federal government is 'targeting a concentrated synthetic byproduct that is an opioid,' underscoring the urgency of state-level action. Despite this clarity, confusion persists among consumers, policymakers, and the media about the fundamental differences between synthetic 7-OH and traditional, plant-based kratom.
'Natural leaf kratom has been used safely for over 50 years by millions of Americans,' Lowe said. 'The danger lies in synthetic manipulation by bad actors to create a product that is 13 times more potent than morphine and is in no way similar to natural kratom. Florida has sent a strong message: there's no place for these dangerous, concentrated opioids in our communities.'
GKC emphasized that the Florida emergency scheduling, which takes immediate effect, aligns with the coalition's mission to ensure kratom remains available in its natural form while keeping harmful synthetic derivatives off the market. The group urged other states to follow Florida's lead and act before synthetic concentrated 7-OH opioid products become more widespread.
'We commend Attorney General Uthmeier and Commissioner Makary for prioritizing consumer safety,' Lowe added. 'This is exactly the kind of targeted enforcement that protects the public without denying consumer access to natural kratom. We stand ready to work with Florida lawmakers, like the Kratom Consumer Protection Act sponsors Senator Collins and Representative Owen, when the legislature convenes in January to codify this scheduling into law.'
For more information, the Global Kratom Coalition has prepared a one-page fact sheet and a video clip of Dr. Makary's July 29 remarks to help clarify the differences between natural kratom and synthetic 7-OH products.
About Global Kratom Coalition
The Global Kratom Coalition is an alliance of kratom consumers, experts, and industry leaders dedicated to protecting access to kratom while advancing scientific research, driving consumer education, and developing robust regulations to protect consumers. For more information, visit globalkratomcoalition.org.
Media Contact
Patrick George
+1 916-202-1982
[email protected]
###
SOURCE: Global Kratom Coalition
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/global-kratom-coalition-florida-ban-synthetic-7-oh-products
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
17 minutes ago
- Business Wire
Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP)
FORT WORTH, Texas--(BUSINESS WIRE)--The Recurrent Respiratory Papillomatosis Foundation (RRPF) is excited to share the news that the U.S. Food and Drug Administration (FDA) has granted full approval to Precigen's Papzimeos (zopapogene imadenovec-drba) under Priority Review for the treatment of adults with Recurrent Respiratory Papillomatosis (RRP). Papzimeos is the first and only FDA-approved treatment for RRP. (See FDA's announcement here) A moment of profound healing for the RRP Community This is truly a remarkable day – the culmination of decades of advocacy, resilience, and unwavering commitment from patients, families, researchers, and supporters. The approval of the first non-surgical treatment for adults with RRP marks not only a scientific milestone, but an inflection point for the entire RRP community. We extend our deepest gratitude to the many individuals and institutions who helped make this breakthrough possible – from the investigators, NIH collaborators, and clinicians who advanced the science, to the industry partners, whose investment and commitment to this community helped bring this treatment to approval. The FDA's announcement is also a deeply personal victory for every voice that has spoken up, every surgery endured, and every hope held steadfast. At RRPF, we are honored to walk alongside this community, championing awareness, supporting research, and amplifying the lived experiences of those affected by this rare disease. We celebrate the light this approval brings and recommit ourselves to the journey ahead, ensuring that patients of every age and living beyond the U.S. can one day access safe, effective and nonsurgical treatments. 'For decades, our community has persevered through an isolating journey of countless surgeries, silence, and uncertainty. Yet while we continued to breathe, we continued to hope. Today, our hope is realized. Today, with the approval of Papzimeos our hope is no longer a dream, it's a reality,' said Kim McClellan, President of RRPF. 'This is a moment of profound healing, not just for the body, but for the spirit of every adult living with RRP. We finally have an FDA-approved treatment that targets the root cause of RRP and with it, the chance for many members of our community to reclaim lives unencumbered by RRP.' Quick facts about Papzimeos (zopapogene imadenovec-drba): The first and only FDA-approved treatment for RRP Approved for adults with RRP The only treatment to target the underlying cause of RRP Papzimeos is a non-replicating adenoviral vector-based immunotherapy designed to generate an immune response directed against papilloma cells expressing HPV 6/11 Delivered via four subcutaneous injections over a 12-week interval Patients can access Papzimeos SUPPORT for personalized services including insurance navigation, financial assistance, and ongoing access support, by calling (866) 827-8180. For Precigen's full release here: For those interested in learning more about resources available to individuals affected by RRP, visit Renewed hope and continued commitment The FDA full approval of Papzimeos is a monumental step forward for the RRP community, but it is not the final destination. RRPF remains deeply committed to advancing research for all patients – including pediatric patients, who continue to face burdens of this disease without an approved therapeutic option, and patients around the world. This milestone fuels our resolve and fortifies our determination to see a future where all people living with RRP have the same hope realized. With strengthened movement, we will continue to advocate, collaborate, and push for the science that brings healing at every age and to every corner of the world. About RRPF The Recurrent Respiratory Papillomatosis Foundation (RRPF) was born from a parent's urgent need to understand and confront a rare, chronic, and potentially life-threatening disease affecting their child. Since 1991, RRPF has been a lifeline for patients and families navigating the isolating journey of RRP – offering connection, advocacy, and hope. What began as a grassroots effort has grown into a mission-driven organization united by the voices of parents, patients, and researchers. RRPF provides vital resources including access to the latest research, updates on clinical trials and medical meetings, and a supportive community for those affected by RRP. The foundation has played a pivotal role in advancing scientific understanding of RRP – contributing to research as authors, funders, and collaborators across multiple studies and initiatives. RRPF honors the legacy of those like Jennifer Woo, a former president of RRPF whose life and career were dedicated to curing RRP, and continues to drive forward research, awareness, and support for all those impacted. While we breathe, we hope. Learn more here:
New York Post
an hour ago
- New York Post
FDA sends warning to 5 sunscreen brands including Supergoop — why they could be pulled from shelves
Some of the summer's hottest beauty products just got burned. 'Beware of sunscreen products in mousse form because they might not be effective,' the Food and Drug Administration cautioned in a post on X this week. The alert follows a wave of warning letters the agency sent to Supergoop!, Vacation Inc. and three other popular brands, accusing them of peddling whipped, mousse and foam sunscreens that flout federal laws. Advertisement 3 Mousse sunscreen may be popular, but the FDA says the product doesn't comply with federal laws regarding over-the-counter drugs. Supergoop! Before you send your beloved sunscreens packing, let's break down the FDA's warnings. The letters — also sent to Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals (makers of TiZo sunscreen) — claim the frothy formulas are 'misbranded.' That's because sunscreens are classified as over-the-counter drugs in the US — and that comes with strict regulations around how they're formulated and marketed. Advertisement Per FDA rules, sunscreens can only be sold as oils, lotions, creams, gels, butters, pastes, ointments, sticks, sprays or powders — not foams, mousses, or whips. To use those formats legally, companies must submit a new drug application with sufficient data proving their safety and effectiveness. 'There are no FDA-approved applications in effect for your drug products,' the agency wrote. Advertisement 3 Because they're marketed to prevent sunburns and skin cancer, sunscreens are regulated as drugs. Vacation The FDA also took aim at Vacation Inc.'s 'Classic Whip Sunscreen,' sold in containers that look like whipped cream cans and advertised as 'dessert for your skin.' 'Packaging drug products in containers that resemble food containers commonly used by adults and children can mislead consumers into mistaking the products for food, which is of particular concern as this increases the risk of accidental ingestion,' the agency warned. Advertisement But the FDA's heat doesn't necessarily mean these fluffy formulas fall short at blocking burns or reducing skin cancer risk. 'The letter does not state that mousse-format sunscreens are less effective or unsafe, nor does it question the quality or performance of our formulation,' Kalani Sunwear told Cosmetics Business, adding that it's 'Sun Mousse SPF 50 is developed and manufactured in Sweden to the highest European standards.' A Supergoop! spokesperson told The Post that the warning 'is focused on product labeling and has nothing to do with its safety, effectiveness or formula,' and added that the company is 'working closely with the FDA to resolve this matter.' 3 To legally sell sunscreens in mousse, foam, or whipped form, companies have to file new drug applications, the FDA said. TikTok/supergoop Still, some outside experts aren't so sure about the whipped format. 'SPF is determined by applying 2 mg/cm^2, which is measured by weight, not volume,' Ava Perkins, a cosmetic chemist and US sunscreen expert, told The Cut. 'Because these mousse sunscreens have so much air incorporated into the product, it can be challenging to know if you're putting on enough, even if it seems like a lot is being dispensed,' she added. Advertisement The FDA's letters, dated August 6, gave each company 15 working days to explain how they plan to fix the issues or prove they're not in violation. Kalani Sunwear has already started taking action, temporarily pulling its mousse-format sunscreen from its US website 'to ensure full compliance with the regulations,' according to CBS News. The Post has reached out to Vacation, Kalani Sunwear, K & Care Organics and Fallien Cosmeceuticals for comment.
Newsweek
an hour ago
- Newsweek
Cheese Recall Over Potential Listeria Risk
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A New York-based cheese company has issued a recall of cases of brie over possible Listeria contamination, the Food and Drug Administration (FDA) announced on Thursday. New York-based Fromi USA is recalling 12 cases of Brie Royal Faucon 1kg after being notified by a foreign manufacturer that its health authority had flagged the contamination risk. Newsweek reached out to Fromi USA for comment via email outside of regular working hours. Why it Matters Listeria infection is the third leading cause of death from foodborne illness in the United States, according to the Centers for Disease Control and Prevention. Each year, an estimated 1,600 people are infected with Listeria, and 260 people die. Listeria monocytogenes can be especially serious for pregnant women, newborns, adults 65 and older and people with weakened immune systems, the CDC said. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, infections can be fatal. Listeria infection can also cause miscarriages and stillbirths among pregnant women. Stock image of brie cheese. Stock image of brie cheese. FRANCOIS GUILLOT/AFP via Getty Images What To Know The product impacted by the recall is: 12 cases of Brie Royal Faucon 1kg The brie was distributed to Cheese Plate Park Slope LLC, located at 400 7th Avenue, 11215, Brooklyn, NY. It was then cut and sold to customers from Cheese Plate Brooklyn - Park Slope LLC, and Cheese Plate Brooklyn: Carroll Gardens from 07/24/2025 through 08/13/2025. The cheese is made from pasteurized cow's milk and is packed 2 units/case. Each cheese is placed in a wooden box and is a bulk product that can be sold either whole or cut into portions. Lot number 615 appears on both the wooden box of each cheese and the case. As of August 14, the FDA has reported no illnesses in the United States tied to the product. What People Are Saying The FDA, on Listeria: "Listeria monocytogenes (L. monocytogenes) is a type of disease-causing bacteria that can be found in many places, including soil, water, sewage, rotting vegetation, and animals. It can survive and grow even under refrigeration. L. monocytogenes can thrive in unsanitary food production conditions, leading to contamination of the food. When people eat food contaminated with L. monocytogenes, they may develop a disease called listeriosis. "L. monocytogenes is generally transmitted when food is harvested, processed, prepared, packed, transported, or stored in manufacturing or production environments contaminated with L. monocytogenes. Environments can become contaminated by raw materials, water, soil, and incoming air. Pets can also spread the bacteria in the home if they eat food contaminated with L. monocytogenes." What Happens Next Consumers who have purchased The Brie Royal Faucon 1kg or cut portions are urged to return them to the place of purchase for a full refund. Customers with questions can contact Fromi USA at (212) 583-4920 from 9 a.m. to 5 p.m. ET, Monday to Friday.
